Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study

NCT01856933 is registered in ClinicalTrials.gov with Heinrich Elinzano, MD as lead sponsor.

NCT NCT01856933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01856933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study
Lead sponsor
Heinrich Elinzano, MD
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
February 28, 2015
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma multiforme, gliosarcoma